Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure
Heart failure is the most common comorbidity of diabetes. The incidence of heart failure in patients with diabetes is about 9%–22%, which is four times higher Than that in patients without diabetes. Heart failure and diabetes are collectively associated with increased morbidity and mortality compare...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=4;spage=618;epage=629;aulast=Sharma |
| _version_ | 1818671445151055872 |
|---|---|
| author | D C Sharma Arthur Asirvatham Parminder Singh |
| author_facet | D C Sharma Arthur Asirvatham Parminder Singh |
| author_sort | D C Sharma |
| collection | DOAJ |
| description | Heart failure is the most common comorbidity of diabetes. The incidence of heart failure in patients with diabetes is about 9%–22%, which is four times higher Than that in patients without diabetes. Heart failure and diabetes are collectively associated with increased morbidity and mortality compared to either condition alone. Several epidemiological studies have demonstrated an increased risk of heart failure in patients with diabetes; moreover, poor glycemic control accounts for the increased risk of heart failure. At present, several oral (metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, etc.) as well as injectable (insulins, glucagon-like peptide 1 receptor agonists) antidiabetic agents are available. However, optimal treatment strategy to achieve adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) and heart failure has not been well studied. In the view of rising prevalence of heart failure in patients with diabetes mellitus, clinicians need to understand the potential implications of antidiabetic agents in patients with heart failure. A group of experts from across India were involved in a consensus meeting in Pondicherry during the National Insulin Summit in November 2015. They evaluated agents currently available for the treatment of diabetes looking at existing scientific evidence relevant to each class of therapy. In addition, the existing guidelines and prescribing literature available with all these agents were also reviewed. Findings from the expert evaluations were then factored into the national context incorporating personal experience and common clinical practices in India. The purpose of this consensus document is to assist the clinicians while treating patients with T2DM and heart failure. |
| first_indexed | 2024-12-17T07:24:07Z |
| format | Article |
| id | doaj.art-e059742624984d5fa57a15561ccc9747 |
| institution | Directory Open Access Journal |
| issn | 2230-8210 |
| language | English |
| last_indexed | 2024-12-17T07:24:07Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj.art-e059742624984d5fa57a15561ccc97472022-12-21T21:58:41ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102017-01-0121461862910.4103/ijem.IJEM_442_16Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failureD C SharmaArthur AsirvathamParminder SinghHeart failure is the most common comorbidity of diabetes. The incidence of heart failure in patients with diabetes is about 9%–22%, which is four times higher Than that in patients without diabetes. Heart failure and diabetes are collectively associated with increased morbidity and mortality compared to either condition alone. Several epidemiological studies have demonstrated an increased risk of heart failure in patients with diabetes; moreover, poor glycemic control accounts for the increased risk of heart failure. At present, several oral (metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, etc.) as well as injectable (insulins, glucagon-like peptide 1 receptor agonists) antidiabetic agents are available. However, optimal treatment strategy to achieve adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) and heart failure has not been well studied. In the view of rising prevalence of heart failure in patients with diabetes mellitus, clinicians need to understand the potential implications of antidiabetic agents in patients with heart failure. A group of experts from across India were involved in a consensus meeting in Pondicherry during the National Insulin Summit in November 2015. They evaluated agents currently available for the treatment of diabetes looking at existing scientific evidence relevant to each class of therapy. In addition, the existing guidelines and prescribing literature available with all these agents were also reviewed. Findings from the expert evaluations were then factored into the national context incorporating personal experience and common clinical practices in India. The purpose of this consensus document is to assist the clinicians while treating patients with T2DM and heart failure.http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=4;spage=618;epage=629;aulast=SharmaAntidiabetic agentsheart failuretype 2 diabetes mellitus |
| spellingShingle | D C Sharma Arthur Asirvatham Parminder Singh Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure Indian Journal of Endocrinology and Metabolism Antidiabetic agents heart failure type 2 diabetes mellitus |
| title | Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| title_full | Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| title_fullStr | Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| title_full_unstemmed | Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| title_short | Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| title_sort | dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure |
| topic | Antidiabetic agents heart failure type 2 diabetes mellitus |
| url | http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=4;spage=618;epage=629;aulast=Sharma |
| work_keys_str_mv | AT dcsharma dosemodificationofantidiabeticagentsinpatientswithtype2diabetesmellitusandheartfailure AT arthurasirvatham dosemodificationofantidiabeticagentsinpatientswithtype2diabetesmellitusandheartfailure AT parmindersingh dosemodificationofantidiabeticagentsinpatientswithtype2diabetesmellitusandheartfailure |